Fungal pneumonia due to molds in patients with hematological malignancies

Journal of Chemotherapy

Volumn 18, Issue 4, 2006, Pages 339-352

  Pagano, L ^a   Fianchi, L ^a   Leone, G ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Fungal pneumonia; Leukemia; Molds

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; ITRACONAZOLE; MICAFUNGIN; PIPERACILLIN PLUS TAZOBACTAM; POSACONAZOLE; RAVUCONAZOLE; STEROID; VORICONAZOLE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ASPERGILLUS; CANDIDA; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMATOLOGIC MALIGNANCY; HUMAN; LUNG ASPERGILLOSIS; MORBIDITY; MORTALITY; MOULD; MYCOSIS; NEPHROTOXICITY; NEUTROPENIA; PNEUMONIA; PROPHYLAXIS; REVIEW; RISK FACTOR; ZYGOMYCETES;

EID: 33749024986     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2006.18.4.339     Document Type: Review

References (168)

1. Walsh TJ, Hiemenz J, Pizzo PA. Evolving risk factors for invasive fungal infections - all neutropenic patients are not the same. Clin Infect Dis. 1994;18:793-798.
2. Patterson TF, Kirkpatrick WR, White M , et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. 13 Aspergillus Study Group. Medicine (Baltimore). 2000;79:250-260.
3. Pagano L, Girmenia C, Mele L, et al. Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA Infection Program. Haematologica. 2001;86:862-870.
4. Palmer LB, Greenberg HE, Schiff MJ. Corticosteroid treatment as a risk factor for invasive aspergillosis in patients with lung disease. Thorax. 1991;46:15-20.
5. Morrison VA, McGlave PB. Mucormycosis in the BMT population. Bone Marrow Transplant. 1993;11:383-388.
6. Ng TT, Robson GD, Denning DW. Hydrocortisone-enhanced growth of Aspergillus spp.: implications for pathogenesis. Microbiology. 1994;140 (Pt 9):2475-2479.
7. Guiot HF, Fibbe WE, van't Wout JW. Risk factors for fungal infection in patients with malignant hematologic disorders: implications for empirical therapy and prophylaxis. Clin Infect Dis. 1994;18:525-532.
8. von Eiff M, Roos N, Fegeler W, et al. Pulmonary fungal infections in immunocompromised patients: incidence and risk factors. Mycoses. 1994;37:329-335.
9. Nucci M, Spector N, Bueno AP, et al. Risk factors and attributable mortality associated with superinfections in neutropenic patients with cancer. Clin Infect Dis. 1997;24:575-579.
10. Martino R, Lopez R, Sureda A, Brunet S, Domingo-Albos A. Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemo-radiotherapy. A single-center experience and review of the literature. Haematologica. 1997;82:297-304.
11. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2002;100:4358-4366.
12. Kami M, Machida U, Okuzumi K, et al. Effect of fluconazole prophylaxis on fungal blood cultures: an autopsy-based study involving 720 patients with haematological malignancy. Br J Haematol. 2002;117:40-46.
13. McNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis. 2001;33:641-647.
14. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mold infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34:909-917.
15. Bag R. Fungal pneumonia in transplant recipients. Curr Opin Pulm Med. 2003;9:193-198.
16. Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood. 1997;90:999-1008.
17. Krcmery V, Krupova I, Denning DW. Invasive yeast infections other than Candida spp. in acute leukaemia. J Hosp Infect. 1999;41:181-194.
18. Pagano L, Finvasive aspergillosisnchi L, Mele L, et al. Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres. Br J Haematol. 2002;117:379-386.
19. Girmenia C, Pagano L, Corvatta L, Mele L, del Favero A, Martino P. The epidemiology of fusariosis in patients with haematological diseases. Gimema Infection Programme. Br J Haematol. 2000;111:272-276.
20. Pagano L, Offidani M, Fianchi L, et al. Mucormycosis in hematologic patients. Haematologica. 2004;89:207-214.
21. Martino P, Venditti M, Micozzi A, et al. Blastoschizomyces capitatus: an emerging cause of invasive fungal disease in leukemia patients. Rev Infect Dis. 1990;12:570-582.
22. Haupt HM, Merz WG, Beschorner WE, Vaughan WP, Saral R. Colonization and infection with Trichosporon species in the immunosuppressed host. J Infect Dis. 1983;147:199-203.
23. Westerman DA, Speed BR, Prince HM. Fatal disseminated infection by Scedosporium prolificans during induction therapy for acute leukemia: a case report and literature review. Pathology (Phila). 1999;31:393-394.
24. Kontoyiannis DP, Peitsch WK, Reddy BT, et al. Cryptococcosis in patients with cancer. Clin Infect Dis. 2001;32:E145-E150.
25. Pagano L, Fianchi L, Caramatti C, et al. Cryptococcosis in patients with hematologic malignancies. A report from GIMEMA-infection. Haematologica. 2004;89:852-856.
26. Roblot F, Le Moal G, Godet C, et al. Pneumocystis carinii pneumonia in patients with hematologic malignancies: a descriptive study. J Infect. 2003;47:19-27.
27. Baddley JW, Pappas PG, Smith AC, Moser SA. Epidemiology of Aspergillus terreus at a university hospital. J Clin Microbiol. 2003;41:5525-5529.
28. Gerson SL, Talbot GH, Hurwitz S, Strom BL, Lusk EJ, Cassileth PA. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med. 1984;100:345-351.
29. Pannuti CS, Gingrich RD, Pfaller MA, Wenzel RP. Nosocomial pneumonia in adult patients undergoing bone marrow transplantation: a 9-year study. J Clin Oncol. 1991;9:77-84.
30. Denning DW. Invasive aspergillosis. Clin Infect Dis. 1998;26:781-803; quiz 804-05.
31. Bennett JE. Aspergillus species. In: Mandell GL, Bennett JE, Dolin R, Eds. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 4th ed. New York, NY: Churchill Livingstone; 1995: 2306-2311.
32. Chen KY, Ko SC, Hsueh PR, Luh KT, Yang PC. Pulmonary fungal infection: emphasis on microbiological spectra, patient outcome, and prognostic factors. Chest. 2001;120:177-184.
33. Lass-Florl C, Salzer GM, Schmid T, Rabl W, Ulmer H, Dierichi MP. Pulmonary Aspergillus colonization in humans and its impact on management of critically ill patients. Br J Haematol. 1999;104:745-7.
34. Lentino JR, Rosenkranz MA, Michaels JA, Kurup VP, Rose HD, Rytel MW. Nosocomial aspergillosis: a retrospective review of airborne disease secondary to road construction and contaminated air conditioners. Am J Epidemiol. 1982;116:430-437.
35. Ruutu P, Valtonen V, Tiitanen L, et al. An outbreak of invasive aspergillosis in a haematologic unit. Scand J Infect Dis. 1987;19:347-351.
36. Anaissie EJ, Kuchar RT, Rex JH, et al. Fusariosis associated with pathogenic fusarium species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections. Clin Infect Dis. 2001;33:1871-1878.
37. Warris A, Klaassen CH, Meis JF, et al. Molecular epidemiology of Aspergillus fumigatus isolates recovered from water, air, and patients shows two clusters of genetically distinct strains. J Clin Microbiol. 2003;41:4101-4106.
38. Anaissie EJ, Stratton SL, Dignani MC, et al. Pathogenic molds (including Aspergillus species) in hospital water distribution systems: a 3-year prospective study and clinical implications for patients with hematologic malignancies. Blood. 2003;101:2542-2546.
39. Revankar SG, Patterson JE, Sutton DA , Pullen R, Rinaldi MG. Disseminated phaeohyphomycosis: review of an emerging mycosis. Clin Infect Dis. 2002;34:467-476.
40. Albelda SM, Talbot GH, Gerson SL, Miller WT, Cassileth PA. Pulmonary cavitation and massive hemoptysis in invasive pulmonary aspergillosis. Influence of bone marrow recovery in patients with acute leukemia. Am Rev Respir Dis. 1985;131:115-120.
41. Young VK, Maghur HA, Luke DA, McGovern EM. Operation for cavitating invasive pulmonary aspergillosis in immunocompromised patients. Ann Thorac Surg. 1992;53:621-624.
42. Pagano L, Ricci P, Nosari A, et al. Fatal haemoptysis in pulmonary filamentous mycosis: an underevaluated cause of death in patients with acute leukemia in haematological complete remission. A retrospective study and review of the literature. Gimema Infection Program (Gruppo Italinvasive aspergillosisno Malattie Ematologiche dell'Adulto). Br J Haematol. 1995 ;89:500-505.
43. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34:7-14.
44. McLintock LA, Holyoake TL, Jones BL. Published rather than proposed definitions for invasive fungal infection must be applied to allow standardization in clinical trials. Clin Infect Dis. 2004;38:1648-1649.
45. Blum U, Windfuhr M, Buitrago-Tellez C, Sigmund G, Herbst EW, Langer M. Invasive pulmonary aspergillosis. MRI, CT, and plain radiographic findings and their contribution for early diagnosis. Chest. 1994;106:1156-1161.
46. Heussel CP, Kauczor HU, Heussel G, Fischer B, Mildenberger P, Thelen M. Early detection of pneumonia in febrile neutropenic patients: use of thin-section CT. AJR Am J Roentgenol. 1997;169:1347-1353.
47. Caillot D, Casasnovas O, Bernard A, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol. 1997;15:139-147.
48. Hauggaard A, Ellis M, Ekelund L. Early chest radiography and CT in the diagnosis, management and outcome of invasive pulmonary aspergillosis. Acta Radiol. 2002;43:292-298.
49. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408-415.
50. Becker MJ, Lugtenburg EJ, Cornelissen JJ, Van Der Schee C, Hoogsteden HC, De Marie S. Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis. Br J Haematol. 2003;121:448-457.
51. Hruban RH, Meziane MA, Zerhouni EA , Wheeler PS, Dumler JS, Hutchins GM. Radiologic-pathologic correlation of the CT halo sign in invasive pulmonary aspergillosis. J Comput Assist Tomogr. 1987;11:534-536.
52. Kim MJ, Lee KS, Kim J, Jung KJ, Lee HG, Kim TS. Crescent sign in invasive pulmonary aspergillosis: frequency and related CT and clinical factors. J Comput Assist Tomogr. 2001;25:305-310.
53. Kim SJ, Lee KS, Ryu YH, et al. Reversed halo sign on high-resolution CT of cryptogenic organizing pneumonia: diagnostic implications. AJR Am J Roentgenol. 2003;180:1251-1254.
54. Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in with neutropenia. J Clin Oncol. 2001;19:253-259.
55. Kami M, Tanaka Y, Kanda Y, et al. Computed tomographic scan of the chest, latex agglutination test and plasma (1AE3)-beta-D-glucan assay in early diagnosis of invasive pulmonary aspergillosis: a prospective study of 215 patients. Haematologica. 2000;85:745-752.
56. Zinck SE, Leung AN, Frost M, Berry GJ, Muller NL. Pulmonary cryptococcosis: CT and pathologic findings. J Comput Assist Tomogr. 2002;26:330-334.
57. Saugier-Veber P, Devergie A, Sulahian A, et al. Epidemiology and diagnosis of invasive pulmonary aspergillosis in bone marrow transplant patients: results of a 5 year retrospective study. Bone Marrow Transplant. 1993;12:121-124.
58. Verweij PE, Stynen D, Rijs AJ, de Pauw BE, Hoogkamp-Korstanje JA, Meis JF. Sandwich enzyme-linked immunosorbent assay compared with Pastorex latex agglutination test for diagnosing invasive aspergillosis in immunocompromised patients. J Clin Microbiol. 1995;33:1912-1914.
59. Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood. 2001;97:1604-1610.
60. Maertens J, Verhaegen J, Demuynck H, et al. Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent for hematological patients at risk for invasive aspergillosis. J Clin Microbiol. 1999;37:3223-3228.
61. Bretagne S, Costa JM, Bart-Delabesse E, Dhedin N, Rieux C, Cordonnier C. Comparison of serum galactomannan antigen detection and competitive polymerase chain reaction for diagnosing invasive aspergillosis. Clin Infect Dis. 1998;26:1407-1412.
62. Kawamura S, Maesaki S, Noda T, et al. Comparison between PCR and detection of antigen in sera for diagnosis of pulmonary aspergillosis. J Clin Microbiol. 1999;37:218-220.
63. Marr KA, Balajee SA, McLaughlin L, Tabouret M, Bentsen C, Welsh TJ. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis. 2004;190:641-9.
64. Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis. 2005;40:1762-9.
65. Adam O, Auperin A, Wilquin F, Bourhis JH, Gachot B, Chachaty E. Treatment with piperacillin-tazobactam and false-positive Aspergillus galactomannan antigen test results for patients with hematological malignancies. Clin Infect Dis. 2004;38:917-20.
66. Herbrecht R, Letscher-Bru V, Oprea C, et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol. 2002;20:1898-1906.
67. Siemann M, Koch-Dorfler M, Gaude M. False-positive results in premature infants with the Platelia Aspergillus sandwich enzyme-linked immunosorbent assay. Mycoses. 1998;41:373-7.
68. Mennink-Kersten MA, Ruegebrink D, Klont RR, et al. Bifidobacterial lipoglycan as a new cause for false-positive Platelia Aspergillus enzyme-linked immunosorbent assay reactivity. J Clin Microbiol. 2005;43:3925-31.
69. Yamakami Y, Hashimoto A, Tokimatsu I, Nasu M. PCR detection of DNA specific for Aspergillus species in serum of patients with invasive aspergillosis. J Clin Microbiol. 1996;34:2464-2468.
70. Hebart H, Loffler J, Meisner C, et al. Early detection of Aspergillus infection after allogeneic stem cell transplantation by polymerase chain reaction screening. J Infect Dis. 2000;181:1713-1719.
71. Einsele H, Quabeck K, Muller KD, et al. Prediction of invasive pulmonary aspergillosis from colonisation of lower respiratory tract before marrow transplantation. Lancet. 1998;352:1443.
72. Spiess B, Buchheidt D, Baust C, et al. Development of a LightCycler PCR assay for detection and quantification of Aspergillus fumigatus DNA in clinical samples from neutropenic patients. J Clin Microbiol. 2003;41:1811-1818.
73. von Eiff M, Zuhlsdorf M, Roos N, Thomas M, Buchner T, van de Loo J. Pulmonary infiltrates in patients with haematologic malignancies: clinical usefulness of non-invasive bronchoscopic procedures. Eur J Haematol. 1995;54:157-162.
74. Pagano L, Pagliari G, Basso A, et al. The role of bronchoalveolar lavage in the microbiological diagnosis of pneumonia in patients with haematological malignancies. Ann Med. 1997;29:535-540
75. McWhinney PH, Kibbler CC, Hamon MD, et al. Progress in the diagnosis and management of aspergillosis in bone marrow transplantation: 13 years' experience. Clin Infect Dis. 1993;17:397-404.
76. Sanguinetti M, Posteraro B, Pagano L, et al. Comparison of real-time PCR, conventional PCR, and galactomannan antigen detection by enzyme-linked immunosorbent assay using bronchoalveolar lavage fluid samples from hematology patients for diagnosis of invasive pulmonary aspergillosis. J Clin Microbiol. 2003;41:3922-3925.
77. Buchheidt D, Hummel M, Schleiermacher D, et al. Prospective clinical evaluation of a LightCycler-mediated polymerase chain reaction assay, a nested-PCR assay and a galactomannan enzyme-linked immunosorbent assay for detection of invasive aspergillosis in neutropenic cancer patients and haematological stem cell transplant recipients. Br J Haematol. 2004;125:196-202.
78. Denning DW, Marinus A, Cohen J, et al. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Fungal Infections Cooperative Group. J Infect. 1998;37:173-180.
79. Kim K, Lee MH, Kim J, et al. Importance of open lung biopsy in the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies. Am J Hematol. 2002;71:75-79.
80. Nosari A, Anghilieri M, Carrafiello G, et al. Utility of percutaneous lung biopsy for diagnosing filamentous fungal infections in hematologic malignancies. Haematologica. 2003;88:1405-1409.
81. Hoffer FA, Gow K, Flynn PM, Davidoff A. Accuracy of percutaneous lung biopsy for invasive pulmonary aspergillosis. Pediatr Radiol. 2001;31:144-152.
82. Perlmutt LM, Johnston WW, Dunnick NR. Percutaneous transthoracic needle aspiration: a review. AJR Am J Roentgenol. 1989;152:451-455.
83. Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis. 2000;30:696-709.
84. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis. 1996;23:608-615.
85. Walsh TJ, Petraitis V, Petraitiene R, et al. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J Infect Dis. 2003;188:305-319.
86. Oppenheim BA, Herbrecht R, Kusne S. The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin Infect Dis. 1995;21:1145-1153.
87. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis. 1998;26:1383-1396.
88. Leenders AC, Daenen S, Jansen RL, et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol. 1998;103:205-212.
89. Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH. Amphotericin B: time for a new "gold standard". Clin Infect Dis. 2003;37:415-425.
90. Ellis M, Spence D, de Pauw B, et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis. 1998;27:1406-1412.
91. Bowden R, Chandrasekar P, White MH, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis. 2002;35:359-66.
92. Denning DW, Lee JY, Hostetler JS, et al. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med. 1994;97:135-144.
93. Caillot D, Bassaris H, McGeer A, et al. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis. 2001;33:e83-e90.
94. Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis. 2004;39:1563-1571.
95. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002;34:563-571.
96. Kinsey S, Jackson G, Holyoake T, McCann S, Gibson B. Results of an open-label study of high-dose liposomal amphotericin B (AmBisome) in the treatment of confirmed fungal infections in high risk patients [abstract]. Br J Haematol. 2004;125, Suppl. 1:62-63. Abstract 202.
97. Steinbach WJ, Stevens DA, Denning DW. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin Infect Dis. 2003;37 suppl 3:S188-S224.
98. Petraitis V, Petraitiene R, Sarafandi AA, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis. 2003;187:1834-1843.
99. Kirkpatrick WR, Perea S, Coco BJ, Patterson TF. Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother. 2002;46:2564-2568.
100. Douglas CM, Abruzzo G, Bowman JC, et al. Caspofungin alone or in combination with itraconazole reduces fungal burden in a neutropenic guinea pig model of disseminated aspergillosis. In: Abstracts of the 42nd Interscience Conference on Antimicrobiology. San Diego, CA: American Society for Microbiology. 2002:416. Abstract M-1819.
101. Aliff TB, Maslak PG, Jurcic JG, et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer. 2003;97:1025-1032.
102. Kontoyiannis DP, Hachem R, Lewis RE, et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer. 2003;98:292-299.
103. Rubin MA, Carroll KC, Cahill BC. Caspofungin in combination with itraconazole for the treatment of invasive aspergillosis in humans. Clin Infect Dis. 2002;34:1160-1161.
104. Castagnola E, Machetti M, Cappelli B, et al. Caspofungin associated with liposomal amphotericin B or voriconazole for treatment of refractory fungal pneumonia in children with acute leukemia or undergoing allogeneic bone marrow transplant. Clin Microbiol Infect. 2004;10:255-257.
105. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis. 2004;39:797-802.
106. Marr KA, Boeckh M, Kim HW. Reply to Cesaro and Visintin. Clin Infect Dis. 2005;40:1075-1076.
107. Reichenberger F, Habicht J, Kaim A, et al. Lung resection for invasive pulmonary aspergillosis in neutropenic patients with hematologic diseases. Am J Respir Crit Care Med. 1998;158:885-890.
108. Baron O, Guillaume B, Moreau P, et al. Aggressive surgical management in localized pulmonary mycotic and non-mycotic infections for neutropenic patients with acute leukemia: report of eighteen cases. J Thorac Cardiovasc Surg. 1998;115:63-68; discussion 68-69.
109. Nakajima J, Takamoto S, Tanaka M, Takeuchi E, Murakawa T. Thoracoscopic resection of the pulmonary aspergilloma: report of two cases. Chest. 2000;118:1490-1492.
110. Matt P, Bernet F, Habicht J, et al. Predicting outcome after lung resection for invasive pulmonary aspergillosis in patients with neutropenia. Chest. 2004;126:1783-8.
111. Yeghen T, Kibbler CC, Prentice HG, et al. Management of invasive pulmonary aspergillosis in hematology patients: a review of 87 consecutive cases at a single institution. Clin Infect Dis. 2000;31:859-68.
112. Schwartz S, Behre G, Heinemann V, et al. Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. Blood. 1999;93:3654-3661
113. Ruijgrok EJ, Vulto AG, Van Etten EW. Efficacy of aerosolized amphotericin B desoxycholate and liposomal amphotericin B in the treatment of invasive pulmonary aspergillosis in severely immunocompromised rats. J Antimicrob Chemother. 2001;48:89-95.
114. Bodey GP, Anaissie E, Gutterman J, Vadhan-Raj S. Role of granulocyte-macrophage colony-stimulating factor as adjuvant therapy for fungal infection in patients with cancer. Clin Infect Dis. 1993;17:705-707.
115. Liles WC, Huang JE, van Burik JA, Bowden RA, Dale DC. Granulocyte colony-stimulating factor administered in vivo augments neutrophil-mediated activity against opportunistic fungal pathogens. J Infect Dis. 1997;175:1012-1015.
116. Peters C, Minkov M, Matthes-Martin S, et al. Leucocyte transfusions from rhG-CSF or prednisolone stimulated donors for treatment of severe infections in immunocompromised neutropenic patients. Br J Haematol. 1999;106:689-696.
117. Hubel K, Dale DC, Engert A, Liles WC. Current status of granulocyte (neutrophil) transfusion therapy for infectious diseases. J Infect Dis. 2001;183:321-328.
118. Strauss RG. Clinical perspectives of granulocyte transfusions: efficacy to date. J Clin Apheresis. 1995;10:114-118.
119. Price TH, Bowden RA, Boeckh M, et al. Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation. Blood. 2000;95:3302-3309.
120. Eucker J, Sezer O, Graf B, Possinger K. Mucormycoses. Mycoses. 2001;44:253-260.
121. DeSouza R, MacKinnon S, Spagnolo SV, Fossieck BE Jr. Treatment of localized pulmonary phycomycosis. South Med J. 1979;72:609-612.
122. Pagano L, Ricci P, Tonso A, et al. Mucormycosis in patients with haematological malignancies: a retrospective clinical study of 37 cases. GIMEMA Infection Program (Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto). Br J Haematol. 1997;99:331-336.
123. Pritchard RC, Muir DB, Archer KH, Beith JM. Subcutaneous zygomycosis due to Saksenaea vasiformis in an infant. Med J Aust. 1986;145:630-631.
124. Tedder M, Spratt JA, Anstadt MP, Hegde SS, Tedder SD, Lowe JE. Pulmonary mucormycosis: results of medical and surgical therapy. Ann Thorac Surg. 1994;57:1044-1050.
125. Chakrabarti A, Kumar P, Padhye AA, et al. Primary cutaneous zygomycosis due to Saksenaea vasiformis and Apophysomyces elegans. Clin Infect Dis. 1997;24:580-583.
126. Eng RHK, Person A, Mangura C, Chmel H, Corrado M. Susceptibility of zygomycetes to amphotericin B, miconazole, and ketoconazole. Antimicrob Agents Chemother. 1981;20:688-690.
127. St-Germain G, Robert A, Ishak M, Tremblay C, Claveau S. Infection due to Rhizomucor pusillus: report of four cases in patients with leukemia and review. Clin Infect Dis. 1993;16:640-645.
128. Otcenasek M, Buchta V. In vitro susceptibility to 9 antifungal agents of 14 strains of Zygomycetes isolated from clinical specimens. Mycopathologia. 1994;128:135-137.
129. Gómez-López A, Cuenca-Estrella M, Monzón A, Rodriguez-Tudela JL. In vitro susceptibility of clinical isolates of Zygomycota to amphotericin B, flucytosine, itraconazole and voriconazole. J Antimicrob Chemother. 2001;48:919-921.
130. Pfaller MA, Messer SA, Hollis RJ, Jones RN. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother. 2002;46:1032-1037.
131. Johnson LB, Kauffman CA. Voriconazole: a new trial antifungal agent. Clin Infect Dis. 2003;36:630-637.
132. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med. 2004;350:950-952.
133. Siwek GT, Dodgson KJ, de Magalhaes-Silverman M, et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis. 2004;39:584-587.
134. Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis. 2004;39:743-746.
135. Del Poeta M, Schell WA, Perfect JR. In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds. Antimicrob Agents Chemother. 1997;41:1835-1836.
136. Pfaller MA, Marco F, Messer SA, Jones RN. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis. 1998;30:251-255.
137. Cornely OA, Schmitz K, Aisenbrey S. The first echinocandin: caspofungin. Mycoses. 2002;45 suppl 3:56-60.
138. Dannaoui E, Meletiadis J, Mouton JW, Meis JF, Verweij PE, and the Eurofung Network. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother. 2003;51:45-52.
139. Greenberg RN, Anstead G, Herbrecht R, Langston A, Marr K, et al. Posaconazole (POS) experience in the treatment of zygomycosis [abstract]. In: Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA: American Society for Microbiology. 2002:476.
140. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis. 2000;30:851-856.
141. Walsh TJ, Goodman JL, Pappas P, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother. 2001;45:3487-3496.
142. Linden P, Lee L, Walsh TJ. Retrospective analysis of the dosage of amphotericin B lipid complex for the treatment of invasive fungal infections. Pharmacotherapy. 1999;19:1261-1268.
143. Herbrecht R, Letscher-Bru V, Bowden RA, et al. Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion. Eur J Clin Microbiol Infect Dis. 2001;20:460-466.
144. Jimenez C, Lumbreras C, Aguado JM, et al. Successful treatment of mucor infection after liver or pancreas-kidney transplantation. Transplantation. 2002;73:476-480.
145. Nucci M, Anaissie EJ, Queiroz-Telles F, et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer. 2003;98:315-319.
146. Al Refai M, Duhamel C, Le Rochais JP, Icard P. Lung scedosporiosis: a differential diagnosis of aspergillosis. Eur J Cardiothorac Surg. 2002;21:938-939.
147. Ellis ME, Clink H, Younge D, Hainau B. Successful combined surgical and medical treatment of fusarium infection after bone marrow transplantation. Scand J Infect Dis. 1994;26:225-228.
148. Cofrancesco E, Boschetti C, Viviani MA, et al. Efficacy of liposomal amphotericin B (AmBisome) in the eradication of Fusarium infection in a leukaemic patient. Haematologica. 1992;77:280-283.
149. Walsh TJ, Lutsar I, Driscoll T, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J. 2002;21: 240-248.
150. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis. 2003; 36: 1122-1131.
151. Donnelly JP, De Pauw BE. Voriconazole - a new therapeutic agent with an extended spectrum of antifungal activity. Clin Microbiol Infect. 2004; 10 suppl 1:107-117.
152. Dignani MC, Anaissie E. Human fusariosis. Clin Microbiol Infect. 2004; 10 suppl 1:67-75.
153. Rodriguez CA, Lujan-Zilbermann J, Woodard P, Andreansky M, Adderson EE. Successful treatment of disseminated fusariosis. Bone Marrow Transplant. 2003;31:411-412.
154. Gil-Lamaignere C, Roilides E, Maloukou A, Georgopoulou I, Petrikkos G, Walsh TJ. Amphotericin B lipid complex exerts additive antifungal activity in combination with polymorphonuclear leucocytes against Scedosporium prolificans and Scedosporium apiospermum. J Antimicrob Chemother. 2002;50:1027-1030.
155. Ortoneda M, Capilla J, Pujol I, et al. Liposomal amphotericin B and granulocyte colony-stimulating factor therapy in a murine model of invasive infection by Scedosporium prolificans. J Antimicrob Chemother. 2002;49;525-529.
156. Meletiadis J, Meis JF, Mouton JW, Rodriquez-Tudela J, Donnelly JP, Verweij PE, Eurofung Network. In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother. 2002;46:62-68.
157. Afeltra J, Dannaoui E, Meis J, Rodriguez-Tudela, Verwij, Eurofung Network. In vitro synergistic interaction between amphotericin B and pentamidine against Scedosporium prolificans. Antimicrob Agents Chemother. 2002;46:3323-3326.
158. Nomdedeu J, Brunet S, Martino R, Altes A, Ausina V, Domingo-Albos A. Successful treatment of pneumonia due to Scedosporium apiospermum with itraconazole: case report. Clin Infect Dis. 1993;16:731-733.
159. Hoffman HL, Rathbun RC. Review of the safety and efficacy of voriconazole. Expert Opin Investig Drugs. 2002;11:409-429.
160. De Pauw BE, Meis JF. Progress in fighting systemic fungal infections in haematological neoplasia. Support Care Cancer. 1998;6:31-38.
161. Kuhlman JE, Fishman EK, Burch PA, Karp JE, Zerhouni EA, Siegelman SS. Invasive pulmonary aspergillosis in acute leukemia. The contribution of CT to early diagnosis and aggressive management. Chest. 1987;92:95-99.
162. Oh YW, Effmann EL, Godwin JD. Pulmonary infections in immunocompromised hosts: the importance of correlating the conventional radiologic appearance with
163. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med. 1999;340:764-771.
164. Prentice HG, Hann IM, Herbrecht R, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol. 1997;98:711-718.
165. Boogaerts M, Winston DJ, Bow EJ, et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med. 2001;135:412-422.
166. Winston DJ, Hathorn JW, Schuster MG, Schiller GJ, Territo MC. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med. 2000;108:282-289.
167. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002;346:225-234.
168. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med. 2004;351:1391-1402.